Ann: Immutep expands Part B of TACTI-002 collaboration trial, page-14

howdy Bylo, the tacti trials were instigated by and paid for by immutep with an $18M supply of keytruda
by Merck......
nowadays,
with the trials expanding Immutep is still paying but dialogue of late is that they have secured
supply of keytruda for the enlarged trials without mention of a dollar value....
Personally I feel Merck are far more interested in these combos now than initially, and indeed
probably more and increasingly engaged with immutep....
At this stage in my mind it is important that immutep maintains control of the tacti trials to maintain
leverage should the Merck/Immutep collaboration progress commercially..
that's just me though, I could be way wrong...